Improving Oncology Clinical Programs by Use of Innovative Designs and Comparing Them via Simulations

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Oncology clinical program design presents significant challenges, with a historical 66% failure rate for phase 3 studies.
• Standard approaches have yielded limited success over the past decade, necessitating improved development strategies.
• Evaluating alternative trial designs is complex due to trade-offs in power, error control, duration, and accuracy.

Purpose of the Study:

• To compare the effectiveness of different hypothetical oncology clinical program designs.
• To investigate the application of innovative statistical methods, specifically adaptive designs, in oncology drug development.
• To assess development strategies using probability of success and expected net present value (eNPV).

Main Methods:

• Comparison of 4 hypothetical oncology development programs, each selecting between two treatments and deciding on phase 3 progression.
• Utilized simulated scenarios to evaluate design alternatives and illustrate key concepts.
• Employed probability of clinical program success and expected net present value (eNPV) as key performance indicators.

Main Results:

• Each successive development strategy demonstrated a distinct and robust improvement in expected net present value (eNPV).
• The study highlighted the potential of adaptive designs to optimize oncology trial pathways.
• Simulations provided a framework for evaluating complex design choices under uncertainty.

Conclusions:

• Adaptive program designs offer a promising approach to enhance the efficiency and success rates of oncology clinical development.
• Expected net present value (eNPV) serves as a robust metric for evaluating and improving oncology development strategies.
• Innovative statistical methods are essential for overcoming the challenges in designing successful oncology clinical programs.